<DOC>
	<DOCNO>NCT01471808</DOCNO>
	<brief_summary>The purpose study investigate evaluate effect different oral antihyperglycaemic agent combine short-term continuous subcutaneous insulin infusion ( CSII ) ( 1.CSII alone ; 2.metformin pioglitazone combine CSII ; 3. sitagliptin combine CSII ) long-term glycemic control β-cell function newly diagnose type 2 diabetic patient .</brief_summary>
	<brief_title>Effects Different Early Intensive Therapies Long-term β-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>newly diagnose type 2 diabetes fast blood glucose ( FBG ) level range 7.0～16.7 mmol/L body mass index ( BMI ) range from20～35kg/m2 Antihyperglycaemic antihyperlipidemic medicationnaive patient severe acute chronic diabetic complication renal dysfunction , blood creatinine≥150µmol/L blood aminotransferase level rise ( 2 time upper normal limit ALT ) • Any severe cardiac disease include congestive cardiac failure , unstable angina myocardial infarct 12 month chronic acute pancreatic disease severe systematic disease malignant tumor female patient incline pregnant treat corticosteroid , immunosuppressing drug cytotoxic drug poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>